← All Kardigan, INC filings

Kardigan, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
KARD
Kardigan, INC
10-Q: Kardigan Reports Strong Clinical Trial Progress, IPO Success
Kardigan, Inc. details advancements in its cardiovascular drug pipeline, successful IPO, and robust cash position, while acknowledging ongoing development risks.